Company Profile

Company Description

Longeveron Inc. is a clinical-stage biotechnology firm focused on developing innovative cellular therapies for aging-related and life-threatening conditions. Its lead candidate, Lomecel-B, is being studied for diseases like Alzheimer's, hypoplastic left heart syndrome, and aging-related frailty. The company leverages proprietary cell-based technology to address unmet medical needs, aiming to improve patient outcomes through regenerative medicine. Research efforts emphasize safety, efficacy, and scalability, positioning it as a potential leader in next-generation treatments for degenerative diseases. Collaborations with academic institutions and healthcare organizations support its mission to advance cutting-edge therapies.